Key Takeaways & Executive Findings
- •• • The closed-loop system achieved a steady-state error of <2% and a response time of <3 seconds, ensuring precise drug dosing and rapid correction of physiological deviations, which is critical for managing acute conditions like hypotension or hyperglycemia. • • The system maintained physiological parameters within target ranges for 95% of operational time, demonstrating high reliability and potential to reduce adverse events due to under- or over-dosing. • • Manual intervention requirements were reduced by 80% compared to conventional open-loop protocols, significantly lowering healthcare workload and enabling more efficient use of clinical resources. • • The IoT platform exhibited a packet loss rate of <0.1% over 24 hours, confirming robust wireless communication for real-time monitoring and control, essential for remote patient management and data integrity.
Abstract
The proliferation of chronic diseases necessitates precise and adaptive drug delivery systems. Conventional open-loop infusion protocols lack real-time feedback, leading to suboptimal therapeutic outcomes and increased risk of adverse events. This study presents a closed-loop drug delivery management system (CDDS) leveraging Internet of Things (IoT) architecture to enable real-time monitoring, data-driven decision-making, and automated dosage adjustment. The system integrates a wireless sensor network for continuous physiological monitoring (e.g., heart rate, blood pressure, glucose levels), a central control unit employing a proportional-integral-derivative (PID) algorithm for dose calculation, and an actuation module for precise drug administration. In a simulated clinical environment, the CDDS achieved a steady-state error of less than 2% and a response time of under 3 seconds for setpoint changes. The system demonstrated robust performance across a range of drug delivery scenarios, maintaining physiological parameters within target ranges for 95% of the operational time. Furthermore, the closed-loop architecture reduced manual intervention requirements by 80% compared to conventional protocols. The IoT-enabled platform also facilitated secure data transmission and remote monitoring, with a packet loss rate of less than 0.1% over a 24-hour continuous operation. These results indicate that the proposed CDDS offers a viable, scalable solution for personalized drug delivery, potentially improving therapeutic efficacy and patient safety in clinical settings.
1. Introduction
Conventional drug delivery systems in clinical practice predominantly rely on open-loop protocols, where dosage is predetermined and administered without real-time feedback from the patient's physiological state. This approach is fraught with limitations: it cannot adapt to dynamic changes in patient condition, leading to suboptimal therapeutic outcomes, increased risk of toxicity, or therapeutic failure. For instance, in critical care settings, manual adjustments by healthcare professionals are often delayed and prone to human error, resulting in prolonged periods of instability. The lack of closed-loop control also hampers the ability to personalize therapy, especially for chronic conditions requiring long-term management. These bottlenecks underscore the urgent need for intelligent systems that can continuously monitor patient status and adjust drug delivery accordingly.
The proposed closed-loop drug delivery management system (CDDS) addresses these challenges by integrating Internet of Things (IoT) architecture with advanced control algorithms. The system leverages a network of wireless biosensors to capture real-time physiological data, which is transmitted to a central control unit that computes optimal dosage using a proportional-integral-derivative (PID) controller. This enables automated, precise, and adaptive drug administration, effectively closing the loop between monitoring and delivery. By doing so, the CDDS not only enhances therapeutic precision but also reduces the burden on healthcare providers, offering a scalable solution for both hospital and home settings. This study details the system architecture, implementation, and experimental validation, demonstrating its clinical feasibility and potential to revolutionize drug delivery management.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming, WANG Fang, CHEN Jing (2025). A Closed-Loop Drug Delivery Management System Based on the Internet of Things: Architecture, Implementation, and Clinical Feasibility. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_215
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the system's response time and steady-state error under varying physiological conditions, and how does it ensure patient safety during rapid changes?
The system achieves a steady-state error of less than 2% and a response time of under 3 seconds for setpoint changes, as demonstrated in simulated clinical scenarios. This rapid response ensures that dosage adjustments are made promptly to maintain physiological parameters within target ranges, thereby minimizing the risk of adverse events during sudden changes in patient condition.
How does the system handle communication failures or data packet loss in the IoT network, and what is the impact on drug delivery accuracy?
The IoT platform exhibited a packet loss rate of less than 0.1% over 24 hours of continuous operation, indicating high reliability. In the event of transient communication failures, the system incorporates a fail-safe mechanism that reverts to a pre-programmed baseline infusion rate, ensuring continuous drug delivery while alerting the central monitoring station. This redundancy prevents interruption of therapy and maintains patient safety.
What is the scalability of the system for multi-patient monitoring in a hospital setting, and how does it manage data from multiple sensors?
The system is designed with a scalable architecture that can accommodate multiple patients by utilizing a centralized control unit capable of processing data from numerous wireless sensor networks. Each patient's data is handled independently, and the system can prioritize alerts based on criticality. In stress tests, the system successfully managed data from up to 50 concurrent patients without degradation in response time or control accuracy.
How does the PID controller handle nonlinearities in drug pharmacokinetics and patient variability?
The PID controller is tuned with conservative gains to ensure stability across a range of patient profiles. However, to address nonlinearities and inter-patient variability, the system incorporates an adaptive mechanism that adjusts controller parameters based on real-time identification of the patient's response. This adaptive tuning improves performance, as evidenced by the 95% time within target range, even in simulated scenarios with varying metabolic rates.
What are the regulatory and safety considerations for translating this system to clinical practice, and what validation has been performed?
The system has undergone extensive in-vitro and in-silico validation, demonstrating reliable performance and safety. For clinical translation, the system is designed to comply with IEC 62304 for medical software and ISO 14971 for risk management. Future work includes animal studies and pilot clinical trials to further validate safety and efficacy, with a focus on obtaining regulatory approvals from bodies such as the FDA and NMPA.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.